Anxiety appears to be associated with increased mortality rate in non-small cell lung cancer (NSCLC) patients, according to a recent study.
Mental illness causes more than one-fifth of total years lost due to disability (YLDs) in the Asia-Pacific region, but only up to 50 percent of those affected receive medical treatment, revealed a recent Janssen Asia Pacific- sponsored study conducted by The Economist Intelligence Unit (EIU). The researchers examined how well countries in this region are doing in terms of treating mental illness outside of institutions and integrating patients into the community, which is the ultimate goal of mental healthcare. The study was based on an index measuring country performance in four areas related to integration (environment, opportunities, access to treatment and governance), as well as interviews with local and international mental healthcare experts.
Schizophrenia remains a global problem creating a profound impact on individual and societal functioning. Common management strategies include a variety of options using oral and injectable antipsychotic drugs, psychotherapy, and strategies to assist the patient to reintegrate into society. Noncompliance with pharmacologic therapies is a very common issue that needs solutions. Professor Christoph Correll of the Department of Psychiatry, Zucker Hillside Hospital Glen Oaks, New York, US, shared his insights on current and novel treatment options for schizophrenia and the advantages of using atypical long-acting injectable (LAI) antipsychotics such as paliperidone palmitate.